Evolutionary dynamics of HIV at multiple spatial and temporal scales

Journal of Molecular Medicine

Volumn 90, Issue 5, 2012, Pages 543-561

  Hill, Alison L ^a   Rosenbloom, Daniel I S ^a   Nowak, Martin A ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

Coevolution; Drug resistance; Evolutionary dynamics; HIV; Immune escape; Virulence

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE TRANSMISSION; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MATHEMATICAL MODEL; MORBIDITY; MORTALITY; MULTIPLE SPATIAL AND TEMPORAL SCALE; PANDEMIC; PATHOGENESIS; PHENOTYPE; RATING SCALE; REVIEW; VIRION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

BIOLOGICAL EVOLUTION; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HOST-PATHOGEN INTERACTIONS; HUMANS; TIME FACTORS;

EID: 84862514242     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-012-0892-1     Document Type: Review

References (173)

1. Fauci AS (2001) Infectious diseases: considerations for the 21st century. Clin Infect Dis 32:675-685. doi:10.1086/319235
2. Pier GB (2008) On the greatly exaggerated reports of the death of infectious diseases. Clin Infect Dis 47:1113-1114. doi:10.1086/592123
3. Spellberg B (2008) Dr. William H. Stewart: mistaken or maligned? Clin Infect Dis 47:294. doi:10.1086/589579
4. Joint United Nations Programme on HIV/AIDS and World Health Organization (2009) AIDS epidemic update. Available: http://www.who.int/hiv/data/en/. Accessed 2 Jan 2012
5. CDC (2011) HIV surveillance-United States, 1981-2008. MMWR 60:689-693
6. Stearns SC, Koella JC (2008) Evolution in health and disease, 2nd edn. Oxford University Press, New York
7. Trevathan WR, Smith EO, McKenna J (2007) Evolutionary medicine and health: new perspectives, 1st edn. Oxford University Press, New York
8. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087-5094
9. Bull JJ, Sanjuán R, Wilke CO (2007) Theory of lethal mutagenesis for viruses. J Virol 81:2930-2939. doi:10.1128/JVI.01624-06
10. Eigen M (2002) Error catastrophe and antiviral strategy. Proc Natl Acad Sci USA 99:13374-13376. doi:10.1073/pnas.212514799
11. Holmes EC (2009) Evolution and emergence of RNA viruses. Oxford University Press, New York
12. Nowk MA (1992) What is a quasispecies? Trends Ecol Evol 7:118-121. doi:10.1016/0169-5347(92)90145-2
13. Kamp C, Wilke CO, Adami C, Bornholdt S (2002) Viral evolution under the pressure of an adaptive immune system: optimal mutation rates for viral escape. Complexity 8:28-33. doi:10.1002/cplx.10067
14. M'Gonigle LK, Shen JJ, Otto SP (2009) Mutating away from your enemies: the evolution of mutation rate in a host-parasite system. Theor Popul Biol 75:301-311. doi:10.1016/j.tpb.2009.03.003
15. Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH (2010) Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol 84:9864-9878. doi:10.1128/JVI.00915-10
16. Rosenbloom DIS, Hill AL, Rabi SA, Siliciano RF, Nowak MA (2012) Antiretroviral dynamics determines HIV evolution and predicts therapy outcome (in press)
17. Ariën KK, Vanham G, Arts EJ (2007) Is HIV-1 evolving to a less virulent form in humans? Nat Rev Micro 5:141-151
18. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK et al (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809
19. Lecossier D, Bouchonnet F, Clavel F, Hance AJ (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112. doi:10.1126/science.1083338
20. Chiu Y-L, Greene WC (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 26:317-353. doi:10.1146/annurev.immunol.26.021607.090350
21. Levy DN, Aldrovandi GM, Kutsch O, Shaw GM (2004) Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci USA 101:4204-4209
22. Thomson MM, Nájera R (2005) Molecular epidemiology of HIV- 1 variants in the global AIDS pandemic: an update. AIDS Rev 7:210-224
23. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J et al (2006) Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313:523-526. doi:10.1126/science.1126531
24. Santiago ML, Range F, Keele BF, Li Y, Bailes E et al (2005) Simian Immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2. J Virol 79:12515-12527. doi:10.1128/JVI.79.19.12515-12527.2005
25. Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K et al (2008) Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 455:661-664. doi:10.1038/nature07390
26. Wolfe ND, Switzer WM, Carr JK, Bhullar VB, Shanmugam Vet al (2004) Naturally acquired simian retrovirus infections in central African hunters. Lancet 363:932-937. doi:10.1016/S0140-6736(04)15787-5
27. May RM, Anderson RM (1987) Transmission dynamics of HIV infection. Nature 326:137-142. doi:10.1038/326137a0
28. Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford University Press, New York
29. de Sousa JD, Müller V, Lemey P, Vandamme A-M (2010) High GUD incidence in the early 20th century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains. PLoS One 5:e9936. doi:10.1371/journal.pone.0009936
30. Katzourakis A, Tristem M, Pybus OG, Gifford RJ (2007) Discovery and analysis of the first endogenous lentivirus. Proc Natl Acad Sci USA 104:6261-6265. doi:10.1073/pnas.0700471104
31. Silvestri G, Sodora DL, Koup RA, Paiardini M, O'Neil SP et al (2003) Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18:441-452
32. Estes JD, Gordon SN, Zeng M, Chahroudi AM, Dunham RM et al (2008) Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol 180:6798-6807
33. Goulder PJR, Watkins DI (2008) Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 8:619-630. doi:10.1038/nri2357
34. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA et al (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283:857-860. doi:10.1126/science.283.5403.857
35. Wertheim JO, Worobey M (2009) Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2. PLoS Comput Biol 5:e1000377. doi:10.1371/journal. pcbi.1000377
36. Holmes EC (2008) Evolutionary history and phylogeography of human viruses. Annu Rev Microbiol 62:307-328. doi:10.1146/annurev.micro.62.081307. 162912
37. Worobey M, Telfer P, Souquière S, Hunter M, Coleman CA et al (2010) Island biogeography reveals the deep history of SIV. Science 329:1487. doi:10.1126/science.1193550
38. Wertheim JO, Kosakovsky Pond SL (2011) Purifying selection can obscure the ancient age of viral lineages. Mol Biol Evol 28:3355-3365. doi:10.1093/molbev/msr170
39. Abecasis AB, Lemey P, Vidal N, de Oliveira T, Peeters M et al (2007) Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form. J Virol 81:8543-8551. doi:10.1128/JVI.00463-07
40. Cvitkovitch DG, Li Y-H, Ellen RP (2003) Quorum sensing and biofilm formation in Streptococcal infections. J Clin Invest 112:1626-1632. doi:10.1172/JCI20430
41. Edwards SV (2009) Is a new and general theory of molecular systematics emerging? Evolution 63:1-19
42. Chung Y, Ané C (2011) Comparing two Bayesian methods for gene tree/species tree reconstruction: simulations with incomplete lineage sorting and horizontal gene transfer. Syst Biol 60:261
43. Valen V (1973) A new evolutionary law. Evol Theory 1:1-30. doi:10.1038/344864a0
44. May RM, Anderson RM (1983) Epidemiology and genetics in the coevolution of parasites and hosts. Proc R Soc B 219:281-313
45. May RM, Nowak MA (1995) Coinfection and the evolution of parasite virulence. Proc R Soc B 261:209-215. doi:10.1098/rspb.1995.0138
46. Nowak MA, May RM (1994) Superinfection and the evolution of parasite virulence. Proc R Soc B 255(1342):81-89
47. Müller V, Fraser C, Herbeck JT (2011) A strong case for viral genetic factors in HIV virulence. Viruses 3:204-216. doi:10.3390/v3030204
48. Shirreff G, Pellis L, Laeyendecker O, Fraser C (2011) Transmission selects for HIV-1 strains of intermediate virulence: a modelling approach. PLoS Comput Biol 7:e1002185. doi:10.1371/journal.pcbi.1002185
49. Herbeck JT,Müller V,Maust BS, Ledergerber B, Torti C et al (2012) Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission. AIDS 26:193-205. doi:10.1097/QAD.0b013e32834db418
50. Dixit NM, Perelson AS (2005) HIV dynamics with multiple infections of target cells. Proc Natl Acad Sci USA 102:8198-8203. doi:10.1073/pnas.0407498102
51. Wodarz D, Levy DN (2011) Effect of multiple infection of cells on the evolutionary dynamics of HIV in vivo: implications for host adaptation mechanisms. Exp Biol Med 236:926-937. doi:10.1258/ebm.2011.011062
52. Wilke CO, Novella IS (2003) Phenotypic mixing and hiding may contribute to memory in viral quasispecies. BMC Microbiol 3:11. doi:10.1186/1471-2180-3-11
53. Novick A, Szilard L (1951) Virus strains of identical phenotype but different genotype. Science 113:34-35
54. Boerlijst MC, Bonhoeffer S, Nowak MA (1996) Viral quasispecies and recombination. Proc R Soc B 263:1577-1584
55. Mostowy R, Kouyos RD, Fouchet D, Bonhoeffer S (2011) The role of recombination for the coevolutionary dynamics of HIV and the immune response. PLoS One 6:e16052. doi:10.1371/journal.pone.0016052
56. Bretscher MT, Althaus CL, Müller V, Bonhoeffer S (2004) Recombination in HIV and the evolution of drug resistance: for better or for worse? Bioessays 26:180-188. doi:10.1002/bies.10386
57. Jung A, Maier R, Vartanian J-P, Bocharov G, Jung Vet al (2002) Recombination: multiply infected spleen cells in HIV patients. Nature 418:144. doi:10.1038/418144a
58. Josefsson L, King MS, Makitalo B, Brännström J, Shao W et al (2011) Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci 108:11199-11204. doi:10.1073/pnas.1107729108
59. Batorsky R, Kearney MF, Palmer SE, Maldarelli F, Rouzine IM et al (2011) Estimate of effective recombination rate and average selection coefficient for HIV in chronic infection. Proc Natl Acad Sci USA. Available: http://www.ncbi.nlm.nih.gov/pubmed/21436045
60. Neher RA, Leitner T (2010) Recombination rate and selection strength in HIV intra-patient evolution. PLoS Comput Biol 6: e1000660. doi:10.1371/journal. pcbi.1000660
61. Nowak MA, Anderson RM, McLean AR, Wolfs TF, Goudsmit J et al (1991) Antigenic diversity thresholds and the development of AIDS. Science 254:963-969
62. Schenzle D (1994) A model for AIDS pathogenesis. Stat Med 13:2067-2079. doi:10.1002/sim.4780131916
63. Nowak MA, May RM, Phillips RE, Rowland-Jones S, Lalloo DG et al (1995) Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 375:606-611
64. Nowak MA, May RM (2000) Virus dynamics: mathematical principles of immunology and virology. Oxford University Press, New York
65. Phillips AN (1996) Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 271:497
66. Simon V, Ho DD, Abdool Karim Q (2006) HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368:489-504. doi:10.1016/S0140-6736(06)69157-5
67. Walker C, Moody D, Stites D, Levy J (1986) CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234:1563-1566. doi:10.1126/science.2431484
68. Lifson JD, Rossio JL, Piatak M, Parks T, Li L et al (2001) Role of CD8+ lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 75:10187-10199
69. Wodarz D, Page KM, Arnaout RA, Thomsen AR, Lifson JD et al (2000) A new theory of cytotoxic T-lymphocyte memory: implications for HIV treatment. Phil Trans R Soc B 355:329-343
70. Wei X, Decker JM, Wang S, Hui H, Kappes JC et al (2003) Antibody neutralization and escape by HIV-1. Nature 422:307-312
71. Chang JJ, Altfeld M (2010) Innate immune activation in primary HIV-1 infection. J Infect Dis 202:S297-S301. doi:10.1086/655657
72. Boutwell CL, Rolland MM, Herbeck JT, Mullins JI, Allen TM (2010) Viral evolution and escape during acute HIV-1 infection. J Infect Dis 202:S309-S314. doi:10.1086/655653
73. Kouyos RD, vonWyl V, Hinkley T, Petropoulos CJ, Haddad M et al (2011) Assessing predicted HIV-1 replicative capacity in a clinical setting. PLoS Pathog 7:e1002321. doi:10.1371/journal.ppat.1002321
74. Goulder PJR, Watkins DI (2004) HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4:630-640. doi:10.1038/nri1417
75. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP et al (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354:453-459. doi:10.1038/354453a0
76. Althaus CL, De Boer RJ (2008) Dynamics of immune escape during HIV/SIV infection. PLoS Comput Biol 4:e1000103.doi:10.1371%2Fjournal.pcbi.1000103
77. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C et al (2005) Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79:13239-13249. doi:10.1128/JVI.79.21.13239-13249. 2005
78. Carlson JM, Brumme ZL, Rousseau CM, Brumme CJ, Matthews P et al (2008) Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol 4:e1000225. doi:10.1371%2Fjournal. pcbi.1000225
79. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D et al (2009) HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 4:e6687. doi:10.1371/journal.pone.0006687
80. Regoes RR, Bonhoeffer S (2005) The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 13:269-277. doi:10.1016/j.tim.2005.04. 005
81. Levy JA (2009) HIV pathogenesis: 25 years of progress and persistent challenges. AIDS 23:147-160. doi:10.1097/QAD.0b013e3283217f9f
82. Sheppard HW, Celum C, Michael NL, O'Brien S, Dean M et al (2002) HIV-1 infection in individuals with the CCR5-[Delta] 32/ [Delta] 32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 29:307
83. Lehmann C, Däumer M, Boussaad I, Sing T, Beerenwinkel N et al (2006) Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol 37:300-304. doi:10.1016/j.jcv.2006.08.008
84. Regoes RR, Wodarz D, Nowak MA (1998) Virus dynamics: the effect of target cell limitation and immune responses on virus evolution. J Theor Biol 191:451-462
85. Kamp C, Bornholdt S (2002) From HIV infection to AIDS: a dynamically induced percolation transition? Proc R Soc B 269:2035-2040. doi:10.1098/rspb. 2002.2095
86. Asquith B (2008) The evolutionary selective advantage of HIV-1 escape variants and the contribution of escape to the HLAassociated risk of AIDS progression. PLoS One 3:e3486. doi:10.1371/journal.pone.0003486
87. Cummins NW, Badley AD (2010) Mechanisms of HIVassociated lymphocyte apoptosis: 2010. Cell Death and Dis 1:e99
88. Alimonti JB, Ball TB, Fowke KR (2003) Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 84:1649-1661. doi:10.1099/vir.0.19110-0
89. Yates A, Stark J, Klein N, Antia R, Callard R (2007) Understanding the slow depletion of memory CD4+ T cells in HIV infection. PLoS Med 4:e177. doi:10.1371/journal.pmed.0040177
90. Galvani AP (2005) The role of mutation accumulation in HIV progression. Proc R Soc B 272:1851-1858. doi:10.1098/rspb.2005.3083
91. Bartha I, Simon P, Müller V (2008) Has HIV evolved to induce immune pathogenesis? Trends Immunol 29:322-328. doi:10.1016/j.it.2008.04.005
92. Deeks SG, Walker BD (2007) Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-416
93. Koup RA, Graham BS, Douek DC (2011) The quest for a T cellbased immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol 11:65-70. doi:10.1038/nri2890
94. O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF et al (2010) Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol 84(14):7018-7028. doi:10.1128/JVI.00548-10
95. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM et al (2010) Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol 84:10820-10831. doi:10.1128/JVI.01084-10
96. Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F et al (2008) HLA associated alterations in replication capacity of chimeric NL4-3 viruses encoding gag-protease from HIV-1 elite controllers. J Virol 83:140-149. doi:10.1128/JVI.01471-08
97. Miura T, Brumme CJ, Brockman MA, Brumme ZL, Pereyra F et al (2009) HLA associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol 83:3407-3412
98. Nowak MA, May RM (1991) Mathematical biology of HIV infections: antigenic variation and diversity threshold. Math Biosci 106:1-21
99. Pantaleo G, Koup RA (2004) Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 10:806-810
100. Korber B, Gnanakaran S (2011) Converging on an HIV vaccine. Science 333:1589-1590. doi:10.1126/science.1211919
101. Blankson JN (2011) The study of elite controllers: a pure academic exercise or a potential pathway to an HIV-1 vaccine? Curr Opin HIVAIDS 6:147-150. doi:10.1097/COH.0b013e3283457868
102. Johnson WE, Desrosiers RC (2002) Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med 53:499-518. doi:10.1146/annurev.med.53. 082901.104053
103. Stearns SC (1977) The evolution of life history traits: a critique of the theory and a review of the data. Annu Rev Ecol Syst 8:145-171
104. Stearns SC (1976) Life-history tactics: a review of the ideas. Q Rev Biol 51(1):3-47
105. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM et al (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10:282-289
106. Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R et al (2009) Adaptation of HIV-1 to human leukocyte antigen class I. Nature 458:641-645. doi:10.1038/nature07746
107. Fryer HR, Scherer A, Oxenius A, Phillips R,McLean AR (2009) No evidence for competition between cytotoxic T-lymphocyte responses in HIV-1 infection. Proc R Soc B. doi:10.1098/rspb.2009.1232
108. Heeney JL, Dalgleish AG, Weiss RA (2006) Origins of HIV and the evolution of resistance to AIDS. Science 313:462-466. doi:10.1126/science.1123016
109. Moir S, Chun T-W, Fauci AS (2011) Pathogenic mechanisms of HIV disease. Annu Rev Pathol 6:223-248. doi:10.1146/annurevpathol-011110-130254
110. Fellay J, Shianna KV, Telenti A, Goldstein DB (2010) Host genetics and HIV-1: the final phase? PLoS Pathog 6:e1001033. doi:10.1371/journal.ppat.1001033
111. Barouch DH (2008) Challenges in the development of an HIV-1 vaccine. Nature 455:613-619
112. Gandon S, Mackinnon MJ, Nee S, Read AF (2001) Imperfect vaccines and the evolution of pathogen virulence. Nature 414:751-756. doi:10.1038/414751a
113. van der Kuyl AC, Cornelissen M (2007) Identifying HIV-1 dual infections. Retrovirology 4:67. doi:10.1186/1742-4690-4-67
114. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860. doi:10.1056/NEJM199803263381301
115. Bonhoeffer S, Nowak MA (1997) Pre-existence and emergence of drug resistance in HIV-1 infection. Proc R Soc B 264:631-637
116. Ribeiro RM, Bonhoeffer S, Nowak MA (1998) The frequency of resistant mutant virus before antiviral therapy. AIDS 12:461
117. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M et al (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14:762-766
118. Sampah MES, Shen L, Jilek BL, Siliciano RF (2011) Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci USA 108:7613-7618. doi:10.1073/pnas.1018360108
119. Hartl DL, Clark AG (2007) Principles of population genetics. Sinauer Associates, Sunderland
120. Pennings PS (2011) Standing genetic variation and the evolution of drug resistance in HIV. Arxiv preprint arXiv:11116164
121. Kouyos RD, Althaus CL, Bonhoeffer S (2006) Stochastic or deterministic: what is the effective population size of HIV-1? Trends Microbiol 14:507-511. doi:16/j.tim.2006.10.001
122. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ et al (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci 106:9403
123. Hockett RD, Michael Kilby J, Derdeyn CA, Saag MS, Sillers M et al (1999) Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 189:1545-1554. doi:10.1084/jem.189.10.1545
124. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M et al (2003) A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77:5037-5038. doi:10.1128/JVI.77.8.5037-5038.2003
125. Ewens WJ (2004) 1.4.3 The stochastic theory. In: Mathematical population genetics: theoretical introduction. Springer, Berlin, pp 27-28
126. Rouzine I, Coffin J (1999) Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc Natl Acad Sci USA 96:10758
127. Brown AJL (1997) Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci USA 94:1862
128. Margot N, Lu B, Cheng A, Miller M (2006) Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903* HIV Med 7:442-450
129. Shen L, Rabi SA, Siliciano RF (2009) A novel method for determining the inhibitory potential of anti-HIV drugs. Trends Pharmacol Sci 30:610-616. doi:10.1016/j.tips.2009.09.003
130. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ (2004) HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 199:283
131. Groot F, Welsch S, Sattentau QJ (2008) Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 111:4660
132. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A et al (2011) Cellto- cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477:95-98. doi:10.1038/nature10347
133. Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS et al (2011) Efavirenz concentrations in CSF exceed IC50 for wildtype HIV. J Antimicrob Chemother 66:354
134. Blankson JN, Persaud D, Siliciano RF (2002) The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53:557-593
135. Crowe S, Zhu T, Muller WA (2003) The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukocyt Biol 74:635-641
136. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB et al (2004) Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 78:10133
137. Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S et al (2010) HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 202:1819
138. Regoes R, Bonhoeffer S (2002) HIV coreceptor usage and drug treatment. J Theor Biol 217:443-457
139. Weinberger AD, Perelson AS, Ribeiro RM, Weinberger LS (2009) Accelerated immunodeficiency by anti-CCR5 treatment in HIV infection. PLoS Comput Biol 5:e1000467. doi:10.1371/journal.pcbi.1000467
140. Beerenwinkel N, Schmidt B,Walter H, Kaiser R, Lengauer T et al (2002) Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci 99:8271-8276. doi:10.1073/pnas.112177799
141. Beerenwinkel N, Lengauer T, Daumer M, Kaiser R,Walter H et al (2003) Methods for optimizing antiviral combination therapies. Bioinformatics 19:i16
142. Lawyer G, Altmann A, Thielen A, Zazzi M, Sönnerborg A et al (2011) HIV-1 mutational pathways under multidrug therapy. AIDS Res Ther 8:26. doi:10.1186/1742-6405-8-26
143. Crotty S, Cameron C, Andino R (2002) Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med 80:86-95. doi:10.1007/s00109-001-0308-0
144. Ávila-Ríos S, Reyes-Terán G, Espinosa E (2007) Cornering HIV: taking advantage of interactions between selective pressures. Med Hypotheses 69:422-431. doi:10.1016/j.mehy.2006.12.012
145. Smith-Franklin BA, Keele BF, Tew JG, Gartner S, Szakal AK et al (2002) Follicular dendritic cells and the persistence of HIVinfectivity: the role of antibodies and Fc-gamma receptors. J Immunol 168:2408
146. Kussell E, Kishony R, Balaban NQ, Leibler S (2005) Bacterial persistence: a model of survival in changing environments. Genetics 169:1807-1814. doi:10.1534/genetics.104.035352
147. Siliciano JD, Siliciano RF (2006) The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. Curr Opin HIV AIDS 1:121-128. doi:10.1097/01.COH.0000209582.82328.b8
148. Rambaut A, Posada D, Crandall KA, Holmes EC (2004) The causes and consequences of HIV evolution. Nat Rev Genet 5:52-61
149. Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV (2005) Stochastic gene expression in a lentiviral positivefeedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122:169-182. doi:10.1016/j.cell. 2005.06.006
150. Weinberger LS, Shenk T (2006) An HIV feedback resistor: autoregulatory circuit deactivator and noise buffer. PLoS Biol 5:e9. doi:10.1371/journal.pbio. 0050009
151. Singh A, Weinberger LS (2009) Stochastic gene expression as a molecular switch for viral latency. Curr Opin Microbiol 12:460-466. doi:10.1016/j.mib. 2009.06.016
152. Pingen M, Nijhuis M, de Bruijn JA, Boucher CAB, Wensing AMJ (2011) Evolutionary pathways of transmitted drugresistant HIV-1. J Antimicrob Chemother 66(7):1467-1480
153. van de Vijver D, Wensing AMJ, Boucher CAB (2007) The epidemiology of transmission of drug resistant HIV-1. In: Leitner T (ed) HIV Sequence Compendium 2007. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos
154. Hué S, Gifford RJ, Dunn D, Fernhill E, Pillay D (2009) Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals. J Virol 83:2645-2654. doi:10.1128/JVI.01556-08
155. Little SJ, Frost SDW, Wong JK, Smith DM, Pond SLK et al (2008) Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 82:5510-5518. doi:10.1128/JVI.02579-07
156. Handel A, Regoes RR, Antia R (2006) The role of compensatory mutations in the emergence of drug resistance. PLoS Comput Biol 2:e137. doi:10.1371/journal. pcbi.0020137
157. Schulz zurWiesch P, Engelstadter J, Bonhoeffer S (2010) Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob Agents Chemother 54:2085-2095, 10.1128/AAC.01460-09
158. Harrison L, Castro H, Cane P, Pillay D, Booth C et al (2010) The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS 24:1917-1922. doi:10.1097/QAD.0b013e32833c1d93
159. Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A et al (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11:363-371. doi:10.1016/S1473-3099(11)70032-9
160. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S (2010) Evolutionary dynamics of complex networks of HIV drugresistant strains: the case of San Francisco. Science 327(5966): 697-701. doi:10.1126/science.1180556
161. zur Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S (2011) Population biological principles of drug-resistance evolution in infectious diseases. Infect Dis 11:236-247. doi:10.1016/S1473-3099(10)70264-4
162. Allen HK, Donato J, Wang HH, Cloud-Hansen KA, Davies J et al (2010) Call of the wild: antibiotic resistance genes in natural environments. Nat Rev Micro 8:251-259. doi:10.1038/nrmicro2312
163. Cohen ML (1992) Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257:1050-1055. doi:10.1126/science.257.5073.1050
164. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J et al (1992) An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 326:1514-1521
165. Cohen T, Murray M (2004) Modeling epidemics of multidrugresistant M. tuberculosis of heterogeneous fitness. Nat Med 10:1117-1121. doi:10.1038/nm1110
166. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED et al (2006) Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20:223-231. doi:10.1097/01.aids.0000199825.34241.49
167. Supervie V, García-Lerma JG, Heneine W, Blower S (2010) HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci USA 107:12381-12386. doi:10.1073/pnas.1006061107
168. Blower S, Bodine E, Kahn J, McFarland W (2005) The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 19:1-14
169. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D et al (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73:10489-10502
170. Lee HY, Perelson AS, Park S-C, Leitner T (2008) Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput Biol 4:e1000240. doi:10.1371%2Fjournal.pcbi.1000240
171. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT et al (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105:7552-7557. doi:10.1073/pnas.0802203105
172. Nowak MA (2006) Evolutionary dynamics: exploring the equations of life. Belknap Press of Harvard University Press, Cambridge
173. Galvani AP (2005) The role of mutation accumulation in HIV progression. Proc R Soc B 272:1851-1858. doi:10.1098/rspb.2005.3083